Clinical and genetic characteristics of the 298 childhood AML patients included in this study, divided by WT1 mutational status
| . | All patients . | WT1 mutated . | WT1 wild-type . | P . |
|---|---|---|---|---|
| Number (%) | 298 (100%) | 35 (11.7%) | 263 (88.3%) | |
| Median age, y | 9.7 | 9.2 | 9.7 | .34 |
| < 3 y, n (%) | 60 | 1 (2%) | 59 (98%) | |
| ≥ 3 and < 10 y, n (%) | 93 | 17 (18%) | 76 (82%) | .008 |
| ≥ 10 y, n (%) | 145 | 17 (12%) | 128 (88%) | |
| Sex (% female) | 46.6% | 48.6% | 46.4% | .81 |
| WBC, × 109/L, median (range) | 38.0 (0.0-534.6) | 57.2 (2.5-332.0) | 34.1 (0.0-534.6) | .007 |
| FAB, n (%) | .60 | |||
| M0 | 15 (5%) | 4 (12%) | 11 (4%) | |
| M1 | 37 (13%) | 6 (18%) | 31 (12%) | |
| M2 | 66 (23%) | 7 (21%) | 59 (23%) | |
| M3 | 21 (8%) | 2 (6%) | 19 (8%) | |
| M4 | 72 (25%) | 8 (24%) | 64 (25%) | |
| M5 | 61 (21%) | 7 (21%) | 54 (21%) | |
| M6 | 6 (2%) | 0 (0%) | 6 (2%) | |
| M7 | 9 (3%) | 0 (0%) | 9 (4%) | |
| Other | 2 (1%) | 0 (0%) | 2 (1%) | |
| Unknown | 9 (3%) | 1 (3%) | 8 (3%) | |
| FLT3/ITD (n = 298), n (%) | 60 (20%) | 15 (43%) | 45 (17%) | < .001 |
| Median allelic ratio (range) | 0.59 (0.21-2.33) | 0.69 (0.32-1.25) | 0.58 (0.21-2.33) | .22 |
| Median ITD length (range) | 54 (18-209) | 51 (18-90) | 55 (20-209) | .44 |
| N- or K-RAS (n = 282), n (%) | 63 (22%) | 8 (25%) | 55 (22%) | .70 |
| c-KIT (n = 283), n (%) | 18 (6%) | 0 (0%) | 18 (7%) | .24 |
| CEBPα (n = 250), n (%) | 20 (8%) | 5 (19%) | 15 (7%) | .03 |
| MLL-PTD (n = 251), n (%) | 6 (2%) | 0 (0%) | 6 (3%) | > .999 |
| NPM1 (n = 293), n (%) | 24 (8%) | 0 (0%) | 24 (9%) | .09 |
| . | All patients . | WT1 mutated . | WT1 wild-type . | P . |
|---|---|---|---|---|
| Number (%) | 298 (100%) | 35 (11.7%) | 263 (88.3%) | |
| Median age, y | 9.7 | 9.2 | 9.7 | .34 |
| < 3 y, n (%) | 60 | 1 (2%) | 59 (98%) | |
| ≥ 3 and < 10 y, n (%) | 93 | 17 (18%) | 76 (82%) | .008 |
| ≥ 10 y, n (%) | 145 | 17 (12%) | 128 (88%) | |
| Sex (% female) | 46.6% | 48.6% | 46.4% | .81 |
| WBC, × 109/L, median (range) | 38.0 (0.0-534.6) | 57.2 (2.5-332.0) | 34.1 (0.0-534.6) | .007 |
| FAB, n (%) | .60 | |||
| M0 | 15 (5%) | 4 (12%) | 11 (4%) | |
| M1 | 37 (13%) | 6 (18%) | 31 (12%) | |
| M2 | 66 (23%) | 7 (21%) | 59 (23%) | |
| M3 | 21 (8%) | 2 (6%) | 19 (8%) | |
| M4 | 72 (25%) | 8 (24%) | 64 (25%) | |
| M5 | 61 (21%) | 7 (21%) | 54 (21%) | |
| M6 | 6 (2%) | 0 (0%) | 6 (2%) | |
| M7 | 9 (3%) | 0 (0%) | 9 (4%) | |
| Other | 2 (1%) | 0 (0%) | 2 (1%) | |
| Unknown | 9 (3%) | 1 (3%) | 8 (3%) | |
| FLT3/ITD (n = 298), n (%) | 60 (20%) | 15 (43%) | 45 (17%) | < .001 |
| Median allelic ratio (range) | 0.59 (0.21-2.33) | 0.69 (0.32-1.25) | 0.58 (0.21-2.33) | .22 |
| Median ITD length (range) | 54 (18-209) | 51 (18-90) | 55 (20-209) | .44 |
| N- or K-RAS (n = 282), n (%) | 63 (22%) | 8 (25%) | 55 (22%) | .70 |
| c-KIT (n = 283), n (%) | 18 (6%) | 0 (0%) | 18 (7%) | .24 |
| CEBPα (n = 250), n (%) | 20 (8%) | 5 (19%) | 15 (7%) | .03 |
| MLL-PTD (n = 251), n (%) | 6 (2%) | 0 (0%) | 6 (3%) | > .999 |
| NPM1 (n = 293), n (%) | 24 (8%) | 0 (0%) | 24 (9%) | .09 |
WBC indicates white blood cell count at diagnosis; and FAB, French-American-British morphology classification.